06:56 AM EST, 02/28/2025 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) reported a Q4 loss Friday of $0.53 per diluted share, widening from a loss of $0.42 a year earlier.

Analysts polled by FactSet expected a loss of $0.38.

Revenue for the quarter ended Dec. 31 was $4.5 million, down from $10.9 million a year earlier.

Analysts surveyed by FactSet expected $15.3 million.

The biopharmaceutical company said it held cash, cash equivalents, and restricted cash of $603.0 million as of Dec. 31, compared with $401.4 million a year earlier, giving it a runway to extend into 2027.

Shares of the company were down 12% in recent premarket activity.